Follow-up of Adult Phenylketonuria (PKU) Patients
Launched by LUDWIG-MAXIMILIANS - UNIVERSITY OF MUNICH · Mar 30, 2010
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • assured clinical diagnose of PKU or proof of mutation in the phenylalanine hydroxylase gene (for PKU patients only)
- • both groups need to hand in a signed consent to participate in the study
- • controls: have to be omnivores and should not be on drugs, which influence the lipid metabolism, during the last 3 months
- • attendance of the last study trial
- Exclusion Criteria:
- • not fulfill the inclusion criteria
About Ludwig Maximilians University Of Munich
Ludwig-Maximilians-University of Munich (LMU Munich) is a prestigious research institution in Germany, renowned for its commitment to advancing medical science and improving patient care through innovative clinical research. As a leading sponsor of clinical trials, LMU Munich leverages its extensive academic resources and interdisciplinary expertise to conduct rigorous studies aimed at evaluating new therapeutic interventions and advancing healthcare knowledge. The university fosters collaboration among researchers, clinicians, and healthcare professionals, ensuring that trials are designed and executed with the highest ethical standards and scientific integrity. Through its dedication to excellence in research, LMU Munich aims to contribute significantly to the development of effective treatments and enhance the overall health outcomes for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Muenchen, , Germany
Patients applied
Trial Officials
Berthold Koletzko, Prof.
Principal Investigator
Ludwig-Maximilians - University of Munich
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials